NUWE Stock Summary and Trading Ideas (Nuwellis | NASDAQ:NUWE)

Nuwellis Inc is a commercial-stage medical device company focused on advancing precision cardiorenal care in critical care settings through the development, manufacture, and commercialization of the Aquadex SmartFlow system for ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.

Nuwellis trades on the NASDAQ stock market under the symbol NUWE.

As of March 27, 2026, NUWE stock price declined to $1.05 with 39,314 million shares trading.

NUWE has a beta of 1.27, meaning it tends to be more sensitive to market movements. NUWE has a correlation of 0.02 to the broad based SPY ETF.

NUWE has a market cap of $2.43 million. This is considered a Sub-Micro Cap stock.

Last quarter Nuwellis reported $2 million in Revenue and -$1.50 earnings per share. This beat revenue expectation by $114,000 and exceeded earnings estimates by $.06.

In the last 3 years, NUWE traded as high as $8,423.23 and as low as $.96.

The top ETF exchange traded funds that NUWE belongs to (by Net Assets): VXF.

NUWE has underperformed the market in the last year with a price return of -97.4% while the SPY ETF gained +12.8%. NUWE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -48.5% and -18.0%, respectively, while the SPY returned -7.9% and -4.5%, respectively.

NUWE support price is $1.03 and resistance is $1.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NUWE shares will trade within this expected range on the day.